TY - JOUR T1 - Genome-wide investigation of DNA methylation in congenital adrenal hyperplasia JF - medRxiv DO - 10.1101/19008524 SP - 19008524 AU - Leif Karlsson AU - Michela Barbaro AU - Ewoud Ewing AU - David Gomez-Cabrero AU - Svetlana Lajic Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/10/11/19008524.abstract N2 - Background Patients with congenital adrenal hyperplasia (CAH) are at risk of long-term cognitive and metabolic sequelae. This study investigates genome-wide DNA methylation in patients with CAH to determine whether there is evidence for epigenomic reprogramming as well as any relationship to patient outcome.Methods We analysed CD4+ T cell DNA from 28 patients with CAH (mean age=18.5 ±6.5 years [y]) and 37 population controls (mean age=17.0 ±6.1 y) with the Infinium-HumanMethylation450 BeadChip array to measure genome-wide locus-specific DNA methylation levels. Effects of CAH, phenotype and CYP21A2 genotype on methylation were investigated as well as the association between differentially methylated CpGs, metabolic profiles (glucose homeostasis and blood lipid profile) and cognitive outcome. In addition, we report data on a small cohort of 11 patients (mean age=19.1, ±6.0 y) with CAH who were treated prenatally with dexamethasone (DEX).Results We identified two CpGs to be associated with patient phenotype: cg18486102 (located in the FAIM2 gene; rho=0.58, adjusted p=0.027) and cg02404636 (located in the SFI1 gene; rho=0.58, adjusted p=0.038). cg02404636 was also associated with genotype (rho=0.59, adjusted p=0.024). We did not observe any effect of DEX on DNA methylation in individuals with CAH. No significant association was found between FAIM2 methylation and cognitive or metabolic outcome. However, SFI1 TSS methylation was associated with fasting plasma HDL cholesterol levels (p=0.035).Conclusion In conclusion, higher methylation levels in CpG sites covering FAIM2 and SFI1 were associated with disease severity. Hypermethylation in these genes may have implications for long-term cognitive and metabolic outcome in patients with CAH.Précis The present study investigates DNA methylation in CD4+ T-cells acquired from patients with congenital adrenal hyperplasia and healthy control subjects. The associations between epigenetic alterations and clinical outcome are also investigated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Marianne and Marcus Wallenberg Foundation, International Fund Congenital Adrenal Hyperplasia (IFCAH)/European Society for Pediatric Endocrinology (ESPE), Stockholm County Council (ALF-SLL), Stiftelsen Frimurare Barnhuset i Stockholm (SFBS), Svenska Läkaresällskapet, Stiftelsen Samariten, Jerringfonden, Sällskapet Barnavård and Wera Ekströms Stiftelse för pediatrisk forskning.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Yesall data are available upon requestCAHcongenital adrenal hyperplasiaSW CAHsalt-wastingSV CAHsimple virilizingDEXdexamethasoneNCnon-classicGCglucocorticoidBbloodPplasmaSserumHDLhigh density lipoproteinLDLlow density lipoproteinWISCWechsler Intelligence Scale for ChildrenWAISWechsler Adult Intelligence ScalePBMCperipheral blood mononuclear cellsMACSmagnetic activated cell sorting450K arrayIllumina Infinium Human Methylation450 BeadChip ArraySNPsingle nucleotide polymorphismFDRfalse discovery rateTSStranscriptional start site. ER -